Therapeutic Area Expertise

Committed to advancing innovative therapies that make a meaningful difference in patients' lives.

From industry-firsts to well-researched indications, MMS brings a wealth of specialized knowledge across therapeutic areas to ensure that your drug development programs are supported by a team that truly understands the unique challenges and opportunities presented. We are proficient in a diverse range of therapeutic areas, including rare diseases, psychedelics, oncology and radiopharmaceuticals, central nervous system (CNS) disorders, and many others. Our deep understanding of these complex indications, combined with our data-driven approach and cutting-edge technology, allows us to be your trusted partner.

Whether you are pioneering new treatments for rare diseases, exploring the potential of psychedelics, or developing groundbreaking oncology therapies, MMS can bring your program to life through comprehensive solutions that focus on the long-term health of your project.

Review our therapeutic area expertise to understand how MMS can help you achieve your development goals across a variety of indications.

In addition to the pivotal therapeutic areas above, MMS global colleagues possess a depth and breadth of industry expertise that is unmatched in other areas.

Suggested For You

news

March 19th, 2025

MMS REMS-focused Technology bolsters Full-Service REMS Solutions

webinar

April 30th, 2025

Advancing Clinical Development with Innovative Trial Design and Regulatory Strategies

perspectives

March 6th, 2025

Overview of FDA Guidance for Industry on Assessment of Ovarian Toxicity in Premenopausal Adults During Development for Oncologic Products

webinar

March 25th, 2025

Overcoming NDA/BLA Submission Challenges: Practical Strategies for Success

perspectives

February 13th, 2025

Helping European Drug Development Companies Succeed in the US Market

news

February 12th, 2025

MMS Acquires Exploristics and KerusCloud Simulation Platform to Expand Biostatistics and Data Science Capabilities as a Global Data-Focused CRO

perspectives

January 30th, 2025

Post-PDUFA VII Updates: FDA Meetings Public Workshop & Lessons Learned

perspectives

January 21st, 2025

REMS Modifications and Revisions: A Retrospective from the Past 12 Months

regulatory intelligence

January 17th, 2025

The FDA’s AI Guidance and its Seven Steps into the Future of Drug Development

regulatory intelligence

January 17th, 2025

New FDA Protocol Deviation Guidance:  Planning for the Things That Don’t Go According to Plan

perspectives

January 9th, 2025

How to Create Efficiencies When Creating Simultaneous NDA and MAA Submissions for the FDA and EMA

perspectives

January 2nd, 2025

Informed Consent in Clinical Research: Understanding its Significance and Sponsor Obligations